Table 4.
Population coverage (%) for specific epitopes containing HLA-binding alleles of MHC class I, class II, as well as combined class I and class II
| population/area | Class I | Class II | Class combined | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Coveragea | Average_hitb | pc90c | Coveragea | Average_hitb | pc90c | Coveragea | Average_hitb | pc90c | |
| Algeria | 0.0% | 0.0 | 0.0 | 83.55% | 1.42 | 0.61 | 83.55% | 1.42 | 0.61 |
| Argentina | 83.23% | 1.73 | 0.6 | 92.37% | 1.78 | 1.07 | 98.72% | 3.51 | 2.03 |
| Australia | 85.67% | 1.71 | 0.7 | 84.53% | 1.31 | 0.65 | 97.78% | 3.02 | 1.63 |
| Austria | 92.54% | 2.28 | 1.09 | 76.61% | 1.24 | 0.43 | 98.26% | 3.52 | 1.85 |
| Belgium | 85.65% | 2.06 | 0.7 | 77.25% | 1.25 | 0.44 | 96.74% | 3.3 | 1.52 |
| Brazil | 84.17% | 1.74 | 0.63 | 85.76% | 1.43 | 0.7 | 97.75% | 3.18 | 1.69 |
| Canada | 0.0% | 0.0 | 0.0 | 93.63% | 1.66 | 1.11 | 93.63% | 1.66 | 1.11 |
| Central Africa | 84.85% | 1.6 | 0.66 | 90.38% | 1.65 | 1.01 | 98.54% | 3.24 | 1.96 |
| Central America | 6.44% | 0.07 | 0.11 | 88.25% | 1.39 | 0.85 | 89.0% | 1.46 | 0.91 |
| Chile | 82.4% | 1.64 | 0.57 | 82.25% | 1.45 | 0.56 | 96.88% | 3.09 | 1.52 |
| China | 78.98% | 1.39 | 0.48 | 86.03% | 1.5 | 0.72 | 97.06% | 2.88 | 1.52 |
| Colombia | 2.84% | 0.03 | 0.1 | 84.34% | 1.45 | 0.64 | 84.79% | 1.48 | 0.66 |
| Croatia | 94.5% | 2.33 | 1.19 | 96.26% | 2.13 | 1.27 | 99.79% | 4.46 | 2.86 |
| Czech Republic | 87.79% | 2.07 | 0.82 | 94.04% | 2.05 | 1.15 | 99.27% | 4.12 | 2.29 |
| Denmark | 0.0% | 0.0 | 0.0 | 93.03% | 2.29 | 1.13 | 93.03% | 2.29 | 1.13 |
| East Africa | 87.8% | 1.9 | 0.82 | 95.27% | 1.96 | 1.2 | 99.42% | 3.86 | 2.31 |
| East Asia | 96.97% | 2.36 | 1.37 | 80.31% | 1.37 | 0.51 | 99.4% | 3.73 | 2.29 |
| England | 95.12% | 2.74 | 1.24 | 91.7% | 2.12 | 1.07 | 99.59% | 4.86 | 2.74 |
| Europe | 92.13% | 2.33 | 1.08 | 89.14% | 1.82 | 0.92 | 99.15% | 4.15 | 2.28 |
| France | 95.51% | 2.63 | 1.28 | 95.14% | 2.32 | 1.24 | 99.78% | 4.94 | 3.04 |
| Germany | 94.18% | 2.5 | 1.18 | 95.55% | 2.27 | 1.25 | 99.74% | 4.77 | 2.87 |
| Greece | 0.0% | 0.0 | 0.0 | 92.99% | 1.88 | 1.1 | 92.99% | 1.88 | 1.1 |
| Hong Kong | 86.36% | 1.59 | 0.73 | 0.0% | 0.0 | 0.0 | 86.36% | 1.59 | 0.73 |
| India | 80.13% | 1.61 | 0.5 | 86.55% | 1.58 | 0.74 | 97.33% | 3.19 | 1.61 |
| Indonesia | 65.87% | 1.02 | 0.29 | 84.82% | 1.31 | 0.66 | 94.82% | 2.33 | 1.22 |
| Iran | 83.59% | 1.46 | 0.61 | 88.19% | 1.62 | 0.85 | 98.06% | 3.08 | 1.77 |
| Ireland Northern | 95.02% | 2.69 | 1.23 | 81.01% | 1.46 | 0.53 | 99.05% | 4.15 | 2.21 |
| Israel | 81.19% | 1.75 | 0.53 | 93.51% | 1.94 | 1.13 | 98.78% | 3.69 | 2.08 |
| Italy | 94.7% | 2.53 | 1.2 | 93.46% | 1.84 | 1.11 | 99.65% | 4.37 | 2.58 |
| Japan | 97.56% | 2.39 | 1.44 | 82.55% | 1.4 | 0.57 | 99.57% | 3.79 | 2.4 |
| Korea; South | 95.86% | 2.26 | 1.27 | 74.06% | 1.16 | 0.39 | 98.93% | 3.42 | 2.08 |
| Lebanon | 0.0% | 0.0 | 0.0 | 84.42% | 1.38 | 0.64 | 84.42% | 1.38 | 0.64 |
| Malaysia | 55.3% | 0.78 | 0.22 | 65.45% | 0.85 | 0.29 | 84.56% | 1.63 | 0.65 |
| Mexico | 88.79% | 1.78 | 0.89 | 84.16% | 1.41 | 0.63 | 98.22% | 3.19 | 1.83 |
| Morocco | 91.75% | 2.32 | 1.07 | 87.3% | 1.61 | 0.79 | 98.95% | 3.93 | 2.19 |
| Netherlands | 0.0% | 0.0 | 0.0 | 91.94% | 2.0 | 1.07 | 91.94% | 2.0 | 1.07 |
| New Zealand | 0.0% | 0.0 | 0.0 | 73.31% | 1.09 | 0.37 | 73.31% | 1.09 | 0.37 |
| North Africa | 87.26% | 1.9 | 0.78 | 87.97% | 1.67 | 0.83 | 98.47% | 3.56 | 2.02 |
| North America | 91.84% | 2.14 | 1.07 | 92.53% | 2.0 | 1.09 | 99.39% | 4.13 | 2.39 |
| Northeast Asia | 80.08% | 1.41 | 0.5 | 86.03% | 1.5 | 0.72 | 97.22% | 2.91 | 1.55 |
| Norway | 0.0% | 0.0 | 0.0 | 94.51% | 2.34 | 1.2 | 94.51% | 2.34 | 1.2 |
| Oceania | 86.77% | 1.74 | 0.76 | 91.99% | 1.77 | 1.06 | 98.94% | 3.5 | 2.09 |
| Oman | 93.04% | 2.14 | 1.11 | 0.0% | 0.0 | 0.0 | 93.04% | 2.14 | 1.11 |
| Paraguay | 0.0% | 0.0 | 0.0 | 45.49% | 0.53 | 0.18 | 45.49% | 0.53 | 0.18 |
| Peru | 80.75% | 1.72 | 0.52 | 81.81% | 1.31 | 0.55 | 96.5% | 3.03 | 1.44 |
| Philippines | 86.69% | 1.73 | 0.75 | 19.14% | 0.2 | 0.12 | 89.24% | 1.92 | 0.93 |
| Portugal | 92.4% | 2.16 | 1.09 | 88.6% | 1.73 | 0.88 | 99.13% | 3.89 | 2.24 |
| Russia | 94.7% | 2.45 | 1.21 | 92.16% | 1.99 | 1.08 | 99.58% | 4.44 | 2.6 |
| Saudi Arabia | 86.23% | 1.96 | 0.73 | 58.23% | 0.8 | 0.24 | 94.25% | 2.76 | 1.23 |
| Serbia | 85.71% | 1.2 | 0.7 | 0.0% | 0.0 | 0.0 | 85.71% | 1.2 | 0.7 |
| Singapore | 79.61% | 1.4 | 0.49 | 74.83% | 0.92 | 0.4 | 94.87% | 2.31 | 1.22 |
| South Africa | 92.34% | 2.14 | 1.09 | 25.52% | 0.26 | 0.13 | 94.3% | 2.4 | 1.2 |
| South America | 86.48% | 1.71 | 0.74 | 84.11% | 1.42 | 0.63 | 97.85% | 3.13 | 1.7 |
| South Asia | 81.86% | 1.66 | 0.55 | 86.6% | 1.59 | 0.75 | 97.57% | 3.24 | 1.67 |
| Southeast Asia | 87.1% | 1.66 | 0.77 | 84.03% | 1.43 | 0.63 | 97.94% | 3.1 | 1.74 |
| Southwest Asia | 78.69% | 1.58 | 0.47 | 85.65% | 1.53 | 0.7 | 96.94% | 3.1 | 1.53 |
| Spain | 80.9% | 1.37 | 0.52 | 89.68% | 1.78 | 0.97 | 98.03% | 3.15 | 1.77 |
| Sweden | 96.98% | 2.44 | 1.33 | 89.41% | 1.85 | 0.94 | 99.68% | 4.3 | 2.57 |
| Thailand | 78.36% | 1.36 | 0.46 | 83.55% | 1.42 | 0.61 | 96.44% | 2.78 | 1.43 |
| Tunisia | 85.74% | 1.91 | 0.7 | 86.64% | 1.66 | 0.75 | 98.09% | 3.57 | 1.9 |
| Turkey | 1.99% | 0.02 | 0.1 | 95.32% | 2.07 | 1.21 | 95.41% | 2.09 | 1.22 |
| Ukraine | 0.0% | 0.0 | 0.0 | 21.22% | 0.42 | 0.25 | 21.22% | 0.42 | 0.25 |
| United Arab Emirates | 13.32% | 0.14 | 0.12 | 32.92% | 0.33 | 0.15 | 41.86% | 0.47 | 0.17 |
| United Kingdom | 0.0% | 0.0 | 0.0 | 38.38% | 0.38 | 0.16 | 38.38% | 0.38 | 0.16 |
| United States | 92.06% | 2.15 | 1.07 | 94.95% | 2.13 | 1.19 | 99.6% | 4.29 | 2.54 |
| Vietnam | 79.28% | 1.42 | 0.48 | 73.86% | 0.97 | 0.38 | 94.58% | 2.39 | 1.21 |
| West Africa | 90.38% | 1.88 | 1.01 | 98.42% | 2.36 | 1.55 | 99.85% | 4.24 | 2.85 |
| West Indies | 94.69% | 2.35 | 1.21 | 93.76% | 1.93 | 1.13 | 99.67% | 4.28 | 2.65 |
| Average | 68.12 | 1.49 | 0.66 | 77.89 | 1.45 | 0.73 | 92.24 | 2.94 | 1.63 |
| Standard deviation | 36.06 | 0.87 | 0.43 | 24.34 | 0.6 | 0.37 | 14.94 | 1.15 | 0.74 |
aProjected population coverage
bAverage number of epitope hits / HLA combinations recognized by the population
cMinimum number of epitope hits / HLA combinations recognized by 90% of the population